TSI Gains New Patent for PEAK ATP

MISSOULA, Mont. TSI Health Sciences received a U.S. Patent (No. 7,629,329), Method for increasing muscle mass and strength through administration of adenosine triphosphate, for its branded ingredient PEAK ATP®. The patented claims cover methods for increasing muscle strength and muscle mass through oral supplementation of ATP (adenosine triphosphate), as well as methods of administering efficacious amounts alone and in combination with other nutritional ingredients.

This newly awarded patent grants TSI extensive protections for PEAK ATP® as a sports nutritional ingredient through a wide range of dosing forms, said Larry Kolb, president of TSIs U.S. operations. TSI is excited about the enhanced protection this patent brings to the companys fast growing sports nutrition customer bases.

Clinical studies have shown PEAK ATP has a dramatic effect on circulation without adversely affecting heart rate or blood pressure. As circulation is the primary vehicle for delivering glucose, nutrients and oxygen to all tissue cells, PEAK ATP has applications for energy, athletic performance and anti-aging. Further, PEAK ATP can elevate the bodys intracellular and extracellular levels of ATP.